Diana Fernandes Lazaro

Dr. Diana Fernandes Lazaro

Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Redox Biology
Verified
Journal Article
Open access
ACAnita Carija
Anita Carija
FPFrancisca Pinheiro
Francisca Pinheiro
JPJordi Pujols
Jordi Pujols
Inês Caldeira BrásInês Caldeira Brás
Inês Caldeira Brás
DLDiana Fernandes Lazaro
Diana Fernandes Lazaro
Salvador VenturaSalvador Ventura
Salvador Ventura
The aggregation of α-synuclein (α-syn) into amyloid fibrils is a major pathological hallmark of Parkinson's disease (PD) and other synucleinopathies. The mechanisms underlying the structural transition of soluble and innocuous α-syn to aggregated neurotoxic forms remains largely unknown. The disordered nature of α-syn has hampered the use of structure-based protein engineering approaches to elucidate the molecular determinants of this transition. The recent 3D structure of a pathogenic α-syn fibril provides a template for this kind of studies. The structure supports the NAC domain being a critical element in fibril formation, since it constitutes the core of the fibril, delineating a Greek-key motif. Here, we stapled the ends of this motif with a designed disulfide bond and evaluated its impact on the conformation, aggregation and toxicity of α-syn in different environments. The new covalent link biases the native structural ensemble of α-syn toward compact conformations, reducing the population of fully unfolded species. This conformational bias results in a strongly reduced fibril formation propensity both in the absence and in the presence of lipids and impedes the formation of neurotoxic oligomers. Our study does not support the Greek-key motif being already imprinted in early α-syn assemblies, discarding it as a druggable interface to prevent the initiation of fibrillation. In contrast, it suggests the stabilization of native, compact ensembles as a potential therapeutic strategy to avoid the formation of toxic species and to target the early stages of PD.


14 May 2022 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SSSamantha L Schaffner
Samantha L Schaffner
Zinah WassoufZinah Wassouf
Zinah Wassouf
DLDiana Fernandes Lazaro
Diana Fernandes Lazaro
MXMary Xylaki
Mary Xylaki
NGNicole Gladish
Nicole Gladish
MKMichael Kobor
Michael Kobor
Parkinson’s disease (PD) is a neurological disorder with complex interindividual etiology that is becoming increasingly prevalent worldwide. Elevated alpha-synuclein levels can increase risk of PD and may influence epigenetic regulation of PD pathways. Here, we report genome-wide DNA methylation and hydroxymethylation alterations associated with overexpression of two PD-linked alpha-synuclein variants (wild-type and A30P) in LUHMES cells differentiated to dopaminergic neurons. Alpha-synuclein altered DNA methylation at thousands of CpGs and DNA hydroxymethylation at hundreds of CpGs in both genotypes, primarily in locomotor behavior and glutamate signaling pathway genes. In some cases, epigenetic changes were associated with transcription. SMITE network analysis incorporating H3K4me1 ChIP-seq to score DNA methylation and hydroxymethylation changes across promoters, enhancers, and gene bodies confirmed epigenetic and transcriptional deregulation of glutamate signaling modules in both genotypes. Our results identify distinct and shared impacts of alpha-synuclein variants on the epigenome, and associate alpha-synuclein with the epigenetic etiology of PD.

20 November 2025 in npj Parkinson's Disease
Verified
Journal Article
Open access
DLDiana Fernandes Lazaro
Diana Fernandes Lazaro
TATriana Amen
Triana Amen
EGEllen Gerhardt
Ellen Gerhardt
CSChengyuan Song
Chengyuan Song
RBRyan Burns
Ryan Burns
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Alpha-synuclein (aSyn) is an intrinsically disordered protein involved in phase separation and several age-associated neurodegenerative disorders, including Parkinson’s disease. However, its function and pathological role remain elusive. Here, we modeled different aSyn assemblies in living cells by exploiting its interaction with synphilin-1 (Sph1). We developed a model that reports on gel- and solid-like inclusions through coexpression of aSyn and Sph1. Distinct morphological differences emerged between VN-aSyn + aSyn-VC and VN-Sph1 + aSyn-VC assemblies, showing unique antibody recognition, proteinase K resistance, and protein mobilities. The VN-Sph1 + aSyn-VC interaction could be manipulated to alter inclusion size and number. These inclusions also contained lysosomes and AP-1 vesicles, aligning with observations in human brain tissue. Our study offers new insight into aSyn aggregation and release, highlighting the importance of Sph1 and other aSyn-interacting proteins in synucleinopathies, which involve diverse copathologies only now beginning to be understood.

17 May 2023 in Research Square
Verified
Preprint
Open access
PDF file
TATriana Amen
Triana Amen
EGEllen Gerhardt
Ellen Gerhardt
PSPatrícia Santos
Patrícia Santos
DMDragomir Milovanovic
Dragomir Milovanovic
GHGünter Höglinger
Günter Höglinger
DLDiana Fernandes Lazaro
Diana Fernandes Lazaro
Alpha-synuclein (aSyn) is an intrinsically disordered protein associated with Parkinson’s disease and other synucleinopathies, where it accumulates in pathognomonic protein inclusions in the brain. However, both the physiological function and the pathological role of aSyn are still elusive. Unlike other proteins also prone to aggregation, expression of aSyn in cell models does not readily result in inclusion formation, and additional insults are required to induce aggregation. In this study, we report for the first time a model that recapitulates the aggregation cascade of aSyn. Our study sheds light on the role of synphilin-1 (Sph1) in aSyn assembly and localization. We show that Sph1 acts as a protein-adaptor for aSyn, and that the coiled-coil domain of Sph1 is essential for inducing inclusion formation. We also demonstrate that the interaction between Sph1 and aSyn can be modulated (genetically, protein levels and heat shock proteins), and that altering the expression levels of each protein affects inclusion size and number per cell. Our study highlights the potential importance of membrane binding for inclusion formation and the presence of lysosomes and AP-1 vesicles in the inclusions. Finally, our study demonstrates that further investigation is necessary to decipher the role of Sph1 and other aSyn-interacting proteins on its biology and pathobiology.

8 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
DLDiana Fernandes Lazaro
Diana Fernandes Lazaro
TATriana Amen
Triana Amen
EGEllen Gerhardt
Ellen Gerhardt
PSPatrícia I. Santos
Patrícia I. Santos
DMDragomir Milovanovic
Dragomir Milovanovic
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Alpha-synuclein (aSyn) is an intrinsically disordered protein that undergoes phase-separation and is associated with several neurodegenerative conditions. However, the function and the pathological role of aSyn are still elusive. Here, we modeled different types of aSyn assemblies in living cells, and developed a model that reports on gel and solid-like inclusions based on the coexpression of aSyn and synphilin-1 (Sph1). We identified striking morphological differences between aSyn-aSyn and Sph1-aSyn assemblies, characterized by distinct antibody recognition patterns, resistance to Proteinase K treatment, and protein mobilities. Importantly, we showed that the interaction between Sph1-aSyn can be manipulated, altering inclusion size and number. Sph1-aSyn interactions were central for inclusion formation and localization, and that inclusions include lysosomes and AP-1 vesicles, consistent with previous studies in human brain tissue. In total, we provide novel insight into the biology of protein aggregation, shedding light on potential therapeutic strategies that extend beyond conventional targets. Deciphering the role of Sph1 and other aSyn-interacting proteins on aSyn biology and pathobiology will be essential for treating synucleinopathies.